Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Biogen Inc.’s chief executive officer said that the impact from US tariffs will be limited, as three-quarters of its product revenue comes from drugs made in the US.

Access our full analysis report here, it’s free. Therapeutics company Biogen (NASDAQ:BIIB) jumped 5.1%. Is now the time to buy Biogen? Access our full analysis report here, it’s free.

Adjacencies and DTx The final focus area at Biogen Digital Health is digital therapeutics and other pharma-adjacent interventions. Hadjiat draws a distinction between patient-facing apps and DTx.

May 1 (Reuters) - Biogen (BIIB.O), opens new tab beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its ...

Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple ...

Ministers are reviewing a controversial medicine tax that pharmaceutical companies say makes Britain 'uninvestable' as part ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 1.8% last quarter ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi behind them and focus on the drug's launch in the region. After months of ...

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: BofA ...